Rationale for using apolipoprotein B and apolipoprotein A-I as indicators of cardiac risk and as targets for lipid-lowering therapy

This publication has 12 references indexed in Scilit:

• Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women: results from the MONICA/KORA Augsburg cohort study
  European Heart Journal, 2004
• Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study
  The Lancet, 2004
• Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
  Journal of the American College of Cardiology, 2004
• Apolipoprotein B and apolipoprotein A‐I: risk indicators of coronary heart disease and targets for lipid‐modifying therapy
  Journal of Internal Medicine, 2004
• Effect of Recombinant ApoA-I Milano on Coronary Atherosclerosis in Patients With Acute Coronary Syndromes
  JAMA, 2003
• European guidelines on cardiovascular disease prevention in clinical practice Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts)
  European Heart Journal, 2003
• Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment
  The Lancet, 2003
• Low-Density Lipoprotein, Non-High-Density Lipoprotein, and Apolipoprotein B as Targets of Lipid-Lowering Therapy
  Circulation, 2002
• High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study
  Published by Elsevier ,2001
• The Friedewald Formula Underestimates LDL Cholesterol at low Concentrations
  cclm, 2001